BioMarin (BMRN) Q2 2026 earnings review
Acquired Growth Masks a Massive Pipeline Failure
BioMarin's Q2 results show the immediate financial impact of the $3.7B Amicus acquisition: revenue surged 20% to $990M, driven by new assets GALAFOLD and POMBILITI+OPFOLDA. However, beneath the headline beat, management quietly buried a devastating pipeline update. BMN 401—the core rationale behind last year's Inozyme acquisition that triggered a $221M charge—failed its pivotal trial and has been entirely discontinued. While raised full-year guidance and Amicus cost-synergy targets ($220M non-GAAP by 2028) are positive, the Inozyme blunder raises serious questions about the company's capital allocation and due diligence.
🐂 Bull Case
Management identified $280M in GAAP ($220M Non-GAAP) cost reductions from the Amicus integration, representing a massive 50% cut to Amicus's 2025 operating expenses. If achieved by 2028, this will drive massive margin expansion.
The Phase 3 CANOPY-HCH-3 study for VOXZOGO met its primary endpoint (+2.33 cm/yr annualized growth velocity). This hits the exact efficacy threshold management previously defined as a 'clear best-in-disease effect', paving the way for a 2027 launch into an estimated 14,000-patient market.
🐻 Bear Case
The discontinuation of BMN 401 destroys the primary value of the Inozyme acquisition completed barely a year ago. It severely undermines management's narrative regarding their 'successful execution' of business development.
The Amicus acquisition was funded with $3.7B in non-convertible debt. Interest expense exploded to $63.3M in Q2 (up from $2.7M a year ago), dragging Non-GAAP EPS down 17% YoY despite 20% revenue growth.
⚖️ Verdict: ⚪
Neutral. The commercial execution on VOXZOGO and the aggressive Amicus synergy targets are highly encouraging. However, the complete failure of BMN 401 is an unignorable red flag regarding management's M&A strategy, and the debt load will artificially suppress EPS growth for the near future.
Key Themes
Inozyme Acquisition Blows Up (BMN 401 Discontinued)
BioMarin quietly announced the discontinuation of BMN 401 across all indications after it failed a co-primary endpoint in the pivotal ENERGY 3 trial. This is a staggering capital allocation failure. BMN 401 was the centerpiece of the Inozyme acquisition, for which BioMarin took a $221M IPR&D charge just last year (25Q3). Management previously touted this as a 'successful execution' of their BD strategy to augment growth; its failure directly contradicts that narrative and demands rigorous investor scrutiny of the remaining pipeline.
Amicus Debt Masks Operational Growth
The Amicus deal successfully accelerated the top line (Revenue +20%), but the balance sheet took a heavy hit. BioMarin is now carrying over $4.1B in debt. Interest expense hit $63.3M for the quarter (an annualized run rate of ~$250M), directly causing the 17% YoY drop in Non-GAAP EPS. Management's pledge to bring gross leverage below 2.5x by mid-2027 is a necessary commitment, but earnings will remain suppressed until this debt is paid down.
VOXZOGO Expansion is Proceeding Flawlessly
VOXZOGO remains the primary organic growth engine, growing 14% YoY to $253M in Q2. More importantly, the future TAM expansion is highly de-risked. The Phase 3 CANOPY-HCH-3 study in hypochondroplasia yielded a +2.33 cm/yr growth velocity increase. The U.S. sNDA is submitted, and the FDA has accepted the sNDA for full approval in achondroplasia (PDUFA Feb 28, 2027). The transition from a single-indication drug to a franchise is materializing.
PALYNZIQ Adolescent Label Triggers Re-acceleration
PALYNZIQ revenue surged 27% YoY to $135M. This validates management's previous commentary about 'encouraging early momentum' following the U.S. label expansion to adolescents (12+) earlier this year, supplemented by the recent European Commission approval for the same demographic. This drug is proving to be a highly durable asset within the legacy metabolic portfolio.
Legacy Enzyme Lumpy Order Timing
Excluding PALYNZIQ, the legacy metabolic business showed weakness. VIMIZIM fell 10% YoY ($194M) and ALDURAZYME fell 21% YoY ($44M). Management attributes this entirely to the timing of large government orders outside the U.S. and order fulfillment to Sanofi. While this lumpiness is historic and expected, it increases reliance on the newer, high-growth assets to carry the quarter.
Rotating the Pipeline: In with BMN 820
To patch the hole left by BMN 401, BioMarin added BMN 820 (an oral CCR2 inhibitor for FSGS) with exclusive U.S. commercialization rights. Addressing a TAM of ~30,000 patients, the Phase 3 ACTION 3 trial is ongoing with data expected in 2028. This represents another shift in the pipeline strategy, moving slightly outside traditional ultra-rare enzyme replacement.
Other KPIs
Collapsed 81% YoY from $241M in 25Q2. The brutal decline is the result of the Amicus acquisition—specifically $84M in acquisition-related costs, $73M in intangible asset amortization, $12M in inventory fair value step-up amortization, and $63M in interest expense.
Despite the massive GAAP net income drop, cash flow from operations remains highly resilient, growing from $359.7M in the prior year. This proves the underlying cash generation of the commercial portfolio is intact and capable of supporting the aggressive debt paydown schedule.
Up drastically from $597M at the end of 2025. Includes $658M in current portion and $3.52B in long-term debt. This is the bill for the Amicus acquisition. Achieving the <2.5x gross leverage target by mid-2027 requires flawless execution on cash generation.
Guidance
Accelerating. The midpoint implies 21% YoY growth, raised from the prior range of $3.825B - $3.925B. This reflects strong first-half performance and the successful onboarding of GALAFOLD and POMBILITI+OPFOLDA revenues.
Accelerating. The low end of the guidance was raised by $25M (from $975M). Global demand remains robust, and breaking the $1 billion blockbuster threshold in a single year marks a major milestone for the franchise.
Accelerating vs prior guide. Raised from $4.85 - $5.05. Despite the heavy interest expense from the Amicus deal (~$200M annualized), the core business outperformance is strong enough to push the full-year EPS target higher. Implies 59% YoY growth from FY25.
Key Questions
BMN 401 Post-Mortem
Given the discontinuation of BMN 401 so shortly after the Inozyme acquisition and the $221M IPR&D charge, what specific flaws in your due diligence process have been identified, and how are you adapting your M&A criteria moving forward?
Amicus Integration Pace
You've outlined an aggressive 50% cut to Amicus's historical operating expenses. How quickly will these synergies be recognized in the P&L over the next 4-6 quarters, and what is the risk of sales force disruption during this cost-cutting phase?
VOXZOGO Competitive Dynamics
With the hypochondroplasia data exceeding expectations, how are you positioning your commercial footprint to secure early market dominance, and are you seeing any changes in U.S. achondroplasia switching behavior due to new entrants?